Emerging retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is creating considerable buzz within the healthcare community. Preliminary clinical research have demonstrated substantial reductions in body weight and advancements in metabolic markers for people with excess weight . Experts believe this unique approach has the p